- #141
kyphysics
- 681
- 442
CVS said they no longer record shots in a vax card anymore. The last one I got recorded was the Pfizer bivalent booster.
Well, I had the Moderna 1st and 2nd dose on 2/10/21 and 3/10/21, which they were aware of, and the Spikevac I had on 10/3 says it expires on 10/30/2023berkeman said:Only if this was your first Covid vax ever...
I didn't get mine at a CVS.kyphysics said:CVS said they no longer record shots in a vax card anymore. The last one I got recorded was the Pfizer bivalent booster.
Yeah, I didn't mean to imply that you did. I was kind of just announcing it as a fact (for everyone to know) w/o any implications in mind.dlgoff said:I didn't get mine at a CVS.
There exist studies, if administration of antipyretic analgesics has a negative effect on the antibody response. I found no such paper specifically related to mRNA vaccine.dlgoff said:Took a couple of Ibuprofen
Source:paper said:The timing of administration of antipyretic analgesics appears to be paramount. In all studies that reported a negative effect on antibody response, the medications were given prophylactically. Interestingly, this effect was not seen when acetaminophen was given only four hours after immunization.6 Additionally, all reported decreases in antibody response occurred only with novel antigen vaccination, with little to no impact observed following booster immunizations.
I was thinking of the Pneu vaccine at some point. I could have added it to the cocktail, but I though 3 was enough (Covid booster, Influenza (for 65+), and RSV.kyphysics said:I am going to sign up for flu this week, but never considered Hep B or Pneu in the past. Anyone else going to get these other ones?
I didn't get RSV yet either. I'm going to get 1 vax every 2 weeks. . .flu ---> RSV ---> tetanus (last one was 25+ years ago) ---> Hep B ---> Pneu.Astronuc said:I was thinking of the Pneu vaccine at some point. I could have added it to the cocktail, but I though 3 was enough (Covid booster, Influenza (for 65+), and RSV.
In Germany, for 60+, vaccination against herpes zoster is officially recommended.Astronuc said:I was thinking of the Pneu vaccine at some point. I could have added it to the cocktail, but I though 3 was enough (Covid booster, Influenza (for 65+), and RSV.
They actually gave me the option of adding the pneumococcal and Herpes zoster vaccines. I decided to defer. I thought 3 was enough in one event.Sagittarius A-Star said:In Germany, for 60+, vaccination against herpes zoster is officially recommended.
This is the case, since in 2018 an inactivated vaccine against it was released.
@berkemanberkeman said:So far no side effects from the latest COV booster.
Talk to your doc, Don. It's probably a good idea to get a 12-lead EKG and other tests. We can discuss it via PMs.dlgoff said:@berkeman
I got the SPIKEVAX on 10/3/23 and I got some heart pains. They are recommending a second shot but I'm not going to get it. See:
https://www.ema.europa.eu/en/news/c...link-very-rare-cases-myocarditis-pericarditis
This seems to revisit an idea that they have been working on since 2020, the rational given in the article is simplistic and unhelpful. The protein products of ACEII expression are clearly important as the entry point of the SARS-CoV-2 virus into cells, it forms part of a functional biochemical network, it doesn't function in isolation. Its not clear why the fact many of the genes associated with immunity are on the X chromosome is important, it may be, but generally the second copy in women is epigenetically turned off. Then of course the presence of the gene doesn't really indicate its expression and that's what effects the protein product levels. In fact, the Genotype-Tissue Expression database reveals 15 e quantitative trait locus variants that regulate the expression of ACE2 in human and the presence of these variants occurs at different frequencies in different ethnic groups. While there do seem to be differences based on ethnicity, the picture isn't clear, it seems that none of these specific variants are associated with hypertension in any of the global studies, ruling out the possibility of a common genetic mechanism for the onset of hypertension and SARS-CoV-2 infection.Astronuc said:I'll be getting Covid (SARS-Cov-2) booster, Influenza and RSV simultaneously. I'll report on any reaction.
Meanwhile - Men at greater risk of severe Covid - and now experts may know why
https://www.msn.com/en-us/health/me...ovid-and-now-experts-may-know-why/ar-AA1hG5w9
See the PF thread on ACE-2 decoy.
https://www.physicsforums.com/threa...solution-to-covid-19-using-ace2-decoy.987905/
https://www.msn.com/en-us/health/ot...hese-are-its-most-common-symptoms/ar-AA1jJniOThe new omicron subvariant has rapidly overtaken other strains, including EG.5 aka Eris, to become the dominant variant in the U.S. As of late October, HV.1 is responsible for more than a quarter of all COVID-19 cases, and health officials are monitoring the new variant amid concerns of a winter COVID-19 surge.
HV.1 accounted for an estimated 25.2% of new COVID-19 cases during the two-week period ending Oct. 28, according to the latest data from the U.S. Centers for Disease Control and Prevention.
After HV.1, the next most common variant in the U.S. was EG.5, which made up 22% of cases, followed by FL.1.5.1 or “Fornax,” and XBB.1.16 or “Arcturus.” (Globally, EG.5 is still the dominant strain, according to the World Health Organization.)
All of the most prevalent COVID-19 strains in the U.S. are offshoots of omicron, which first emerged in November 2021.
HV.1 is part of the omicron family. “You can almost think of HV.1 as a grandchild of omicron,” says Schaffner. HV.1 is a sublineage of omicron XBB.1.9.2 and a direct descendent of EG.5, according to the CDC's SARS-CoV-2 lineage tree.
. . .
However, there are a few highly mutated strains which have set off alarm bells. These include BA.2.86 or Pirola, which has an extra 36 mutations that differentiate it from XBB.1.5., and a newer variant called JN.1, which has one more mutation than Pirola.
Fortunately, neither BA.2.86 nor JN.1 are common in the U.S. right now, according to the CDC — JN.1 is so rare that it makes up fewer than 0.1% of SARS-CoV-2 cases.
As for HV.1, it rapidly gained steam after it was first detected this past summer. In late July, HV.1 accounted for just 0.5% of COVID-19 cases in the U.S., CDC data show. By Sept. 30, HV.1 made up 12.5% of cases, and by November, it was the dominant strain.
The new boosters have been reformulated to target omicron XBB.1.5, which was the dominant COVID variant for most of 2023. While XBB.1.5 has since been overtaken by HV.1, Eris, Fornax and Arcturus, it is still closely related to these newer strains.
RSV not available in the UK till June this year. I was not offered it with my flu/Covid jab last month.kyphysics said:I didn't get RSV yet either. I'm going to get 1 vax every 2 weeks. . .flu ---> RSV ---> tetanus (last one was 25+ years ago) ---> Hep B ---> Pneu.
Hopefully that catches me up with everything by December. I might combine a few, but just want to research to see it's okay (since I have some complicated diabetes).
I got my flu shot w/ zero side-effects (I've never had any ever. . .only with the COVID shots). I will get tetanus (not RSV) next week.pinball1970 said:RSV not available in the UK till June this year. I was not offered it with my flu/Covid jab last month.
I will discuss with my GP next check up.
https://fortune.com/well/2023/12/01...ic-tripledemic-winter-2023-respiratory-virus/COVID will likely reach levels in December not yet seen this year, combining with surges of flu, RSV, and other pathogens for a winter not so different from last year’s “tripledemic,” experts say.
https://news.yahoo.com/growing-covid-19-variant-taken-184948041.htmlJN.1 was first detected in the U.S. in September. It had previously been classified with BA.2.86, or Pirola, a descendant of the omicron family, which some researchers early on worried could pose risks, but cases have recently declined in CDC estimates. In contrast, the original omicron variant overwhelmed hospital systems in 2022.
So far, it appears JN.1 doesn’t present a greater risk. Vaccination and previous infection also appear to help reduce the risk of serious illness from JN.1.
https://www.msn.com/en-us/health/ot...y-high-respiratory-illness-levels/ar-AA1lsJ1lAccording to the CDC, Louisiana and South Carolina are currently facing "very high levels" of respiratory illnesses. Meanwhile, New York, North Carolina, Georgia, Florida, Alabama, Mississippi, Tennessee, Texas, California, New Jersey, Nevada, New Mexico, Colorado, and Wyoming are witnessing "high levels" of respiratory illnesses. Additionally, eight more states and Washington, D.C., are showing an upward trend at a moderate level.
High percentages of positive COVID-19 cases, emergency department visits, and hospitalizations are reported nationwide, with a total of 22,513 admissions in the past week.
Furthermore, the nationwide rates of emergency department visits and hospitalizations due to influenza are on the rise. Simultaneously, hospitalization rates for RSV are also increasing among both young children and older adults.
Highly mutated COVID variant BA.2.86—close ancestor of globally dominant “Pirola” JN.1—may lead to more severe disease than other Omicron variants, according to two new studies published Monday in the journal Cell.
In one study, researchers from Ohio State University performed a variety of experiments using a BA.2.86 pseudovirus—a lab-created version that isn’t infectious. They found that BA.2.86 can fuse to human cells more efficiently and infect cells that line the lower lung—traits that may make it more similar to initial, pre-Omicron strains that were more deadly.
In the other study, researchers in Germany and France came to the same conclusion. “BA.2.86 has regained a trait characteristic of early SARS-CoV-2 lineages: robust lung cell entry,” the authors wrote. The variant “might constitute an elevated health threat as compared to previous Omicron sublineages,” they added.
I read the same article, which was accompanied by a video.kyphysics said:New, highly mutated COVID variants ‘Pirola’ BA.2.86 and JN.1 may cause more severe disease, new studies suggest
Tissue samples taken during autopsies from the heart, kidney, liver, and lymph nodes continued to show suppression of these mitochondrial genes long after the virus had been cleared from the body. The reason for this continued suppression is unclear. In tandem with reduced mitochondrial function in these tissues, the researchers saw an upregulation of genes related to cellular stress.
“The continued dysfunction we observed in organs other than the lungs suggests that mitochondrial dysfunction could be causing long-term damage to the internal organs of these patients,” Wallace says.
A study in the Lancet, deaths from under vaccination.Nik_2213 said:Tangential, the prospect of another new, nasty Covid variant coming through seems unlikely to change vaxx attitudes before distancing / masking re-introduced...
Based on casual enquiry --'NO Control Group'-- around usual dozen or so immediate neighbours and acquaintances, we again divide into my 'fully vaccinated' faction --Covid, Seasonal Flu & Decadal Pneumonia-- and the minimally vaccinated rest, be they out-right anti-vaxxers, efficacy disbelievers and/or 'Couldn't Be Bothered'...
Upside, UK is safely through the Winter Solstice, past the peak of family gatherings and crowd-drawing, virus-spreading 'Winter Sales'. Down-side, IIRC, waste-water monitoring shows an unsettling rise in viral loads...
Take Care Out There !!
I need to digest this. Informative as usual sir.Laroxe said:I think it's entirely predictable that we are seeing new variants, in fact there are many more around than what we see reported, we only see reports when one variant starts to be seen more frequently. Identified genetic changes don't tell us very much really, they happen all the time, particularly in RNA viruses & most of these will either be damaging to the virus or largely irrelevant. Even the identified changes in the genome that affect the structure of the spike protein may not cause predictable changes. The concern that the Pirola variant may have advantages in gaining cell entry don't seem likely, none of the Omicron variants appear to have any difficulty with this, in some cases the incubation period between exposure and symptom onset can be 1-2 days, that's fast.
I will also say that these studies on the risk of severe outcomes with different vaccine doses are less than helpful, in fact the lancet article might as well have been written in Russian, and I don't speak Russian. They seem to have forgotten to mention the study population of roughly 64 million, and I couldn't find any overall hazard ratio. They also fail to make what they mean by undervaccinated, the guidelines at the time specified different numbers of vaccinations for different age groups. At the time of the study to be fully vaccinated was to have received two with the third considered a booster dose. A second booster became available for most people in September of 2022, after this study.
I suspect attempting to provide some sort of general estimate of risk, when we consider the range of significant variables, was a rater pointless exercise. I've provided a link to a rather less opaque study that looks at similar issues after the 2nd booster, naturally they use different cut off points, so comparisons are useless. It does however make some interesting points, the first is that even after the 2nd booster, when compared to people under 50, those over 80 were 10.43 times more likely to experience severe outcomes. The study also demonstrated the effects of the time between vaccinations, which is increasingly identified as important. People receiving the booster after a period of less than 24 weeks from a previous vaccination were actually at increased risk, I've seen it suggested that a vaccination given too soon can actually damage the immune status. Finally, they report the effects of BMI on risk suggesting
For BMI, we found that those classified as underweight (BMI<18.5) were at greater risk of a severe outcome
than those classified as overweight (BMI 25.0–29.9). Additionally, those classified as a healthy weight (BMI 18.5–24.9) were 1.36(1.25–1.48) times more likely to experience a severe outcome than those classified as overweight. This seems to match the findings of Fragal on BMI and mortality, perhaps you need some stored calories to survive in intensive care. Obesity is still a significant risk.https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(23)00235-1/fulltext
That's disappointing.PeroK said:Sadly, Campbell seems to have sunk into a full-scale COVID "big pharma" conspiracy theorist and ardent climate change denier.
One of the things that frustrates me most is to see two old men (in their 70's) trash climate science when they are not going to have to live with the consequences.Astronuc said:That's disappointing.
I would be one of those who watched his videos religiously. Then one day, he stopped making sense. One of his latest 'things' is 'excess deaths'. I suspect it's one of those 'it's outside his field of expertise so he's getting it VERY wrong' type of things. Not that I'm even remotely familiar with the topic, but after a few hours of analysis, I can make 'excess deaths' numbers do whatever I want.PeroK said:I know that during the pandemic several people watched John Campbell's videos on COVID data. Sadly, Campbell seems to have sunk into a full-scale COVID "big pharma" conspiracy theorist and ardent climate change denier. I won't link to the video that YouTube just served up, but it was a bit of a shock.
Talking of Paxlovid I came across this articleAstronuc said:That's disappointing.
I can attest to the effectiveness of masks, vaccines and Paxlovid. I'm on day 3 of taking Paxlovid, starting last Friday evening after testing positive for Covid. Thursday evening, I was showing symptoms similar to a normal common (Rhinovirus/Coronavirus) cold - mostly congestion, runny nose, slight headache and chills; I also has a slight and infrequent cough. I called my doctor on Friday morning, but couldn't get an appointment until Friday afternoon. I tested positive, so the doctor prescribed Paxlovid, and I was able to start taking the medication Friday evening. On Friday, I was having much stronger symptoms including fatigue, but fortunately, no strong cough. After 24 hours on Paxlovid, the symptoms became muich milder, and the congestion and runny nose abated, and now two days later, I feel more or less normal.
My son had tested postive on Wednesay afternoon. He was not prescribed Paxlovid, since it is currently reserved for those under 18, 50 or older, and those at risk of medical complication, or who have some health vulnerability. I think he should have insisted, since he was quite ill, and this was his second time, and his symptoms were more severe, including changes to his senses of smell and taste, and he had a fever and cough. He did not get the recent booster.
My wife tested negative for Covid on Friday evening, but tested again Saturday morning with a positive result. She started showing symptoms Friday night into Saturday.
We always wear masks in public and my son wears a mask at work, but he does remove the mask to eat and drink. He either got the virus at work, or Wednesday (12 days ago) at lunch with a coworker, and was probably infection on the following Saturday when we drove about 90 miles to visit a museum, and returned during the late afternoon. In public we all wore masks at the museum, but not during the car ride.
That's an interesting twist on chemistry, replacing H with D in a molecule to affect its function.pinball1970 said:Talking of Paxlovid I came across this article
https://medicalxpress.com/news/2024-01-antiviral-medication-covid-patients-access.html
"Lemieux and her colleagues have modified a specific area of the molecule in the active drug that enables it to stay in the system—meaning an additional "booster" drug is not necessary. This could help widen the use of the drug and allow more people to safely treat their COVID infection"
The paper was published in Aug so may have mentioned somewhere else on PF
https://pubs.acs.org/doi/10.1021/acsbiomedchemau.3c00039
https://www.yalemedicine.org/news/13-things-to-know-paxlovid-covid-19Paxlovid is an antiviral therapy that consists of two separate medications packaged together. When you take your three-pill dose, two of those pills will be nirmatrelvir, which inhibits a key enzyme that the COVID virus requires in order to make functional virus particles. After nirmatrelvir treatment, the COVID virus that is released from the cells is no longer able to enter uninfected cells in the body, which, in turn, stops the infection. The other is ritonavir, a drug that was once used to treat HIV/AIDS but is now used to boost levels of antiviral medicines.
As a COVID-19 treatment, ritonavir essentially shuts down nirmatrelvir’s metabolism in the liver, so that it doesn’t move out of your body as quickly, which means it can work longer—giving it a boost to help fight the infection.
Tamiflu is an antiviral drug that reduces flu symptoms. Both are prescription-only oral antiviral pills given early in illness.
Tamiflu is taken twice a day for five days, and it must be started within 48 hours of flu onset. “When you give a patient Tamiflu beyond that, it doesn’t really change the course of their flu,” Dr. Roberts says.
But there are also differences between the two, starting with the way they were studied, Dr. Topal adds. Researchers showed that Paxlovid can prevent hospitalization and death. But since influenza causes fewer severe cases, clinical trials focused on whether Tamiflu could shorten the length of flu illness—which it did, he says.
nsaspook said:https://www.wsj.com/health/wellness/covid-guidelines-2024-cdc-symptoms-contagious-cdefb6b8
It’s Official: We Can Pretty Much Treat Covid Like the Flu Now. Here’s a Guide.
New guidelines from the CDC Friday bring Covid precautions in line with with those of other respiratory viruses
https://www.cdc.gov/respiratory-viruses/background/index.html